|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| *With Combo Drug* | | *Without Combo Drug* | |  |  |  |  |  |
| **HR** | **P-value** | **HR** | **P-value** | **HR Ratio** | **AR** | **Combo Drug** | **Downstream Protein** | **ExpNum** |
| 1.09 | 4.61E-01 | 0.93 | 6.33E-04 | 1.17 | Hypertension | Loperamide | POMC | Exp22 |
| 1.00 | 1.00E+00 | 0.88 | 6.65E-02 | 1.14 | Pancreatitis | Sucralfate | EGF | Exp35 |
| 1.17 | 2.86E-03 | 1.15 | 9.72E-13 | 1.01 | Hypertension | Sucralfate | EGF | Exp17 |
| 1.13 | 1.29E-02 | 1.12 | 1.48E-12 | 1.01 | Edema | Aliskiren | REN | Exp2 |
| 1.00 | 1.00E+00 | 1.02 | 6.74E-01 | 0.98 | Myopathy | Sucralfate | EGF | Exp29 |
| 1.08 | 6.94E-01 | 1.20 | 9.55E-21 | 0.90 | Hypertension | Gentamicin | LRP2 | Exp8 |
| 0.96 | 5.24E-01 | 1.12 | 3.48E-08 | 0.85 | Hypertension | Misoprostol | PTGER4 | Exp18 |

**Table 4. Additional HR ratios estimated from EHR-ML analysis.** Network and non-network class drugs are listed in **Sup. File 6** and are referenced by the experimental number (“ExpNum”).